Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348237 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
A Phase 1 study of End Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT07348237 is a Phase 1 study of End Stage Renal Disease and Renal Impairment that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT07348237, a Phase 1 study of End Stage Renal Disease and Renal Impairment, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
Conditions Studied
Interventions
- DRUG MK-2828
Study Locations (3)
Florida
- Panax Clinical Research ( Site 0003) - Miami Lakes
- Floridian Clinical Research ( Site 0001) - Miami Lakes
- Orlando Clinical Research Center ( Site 0002) - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2026-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07348237
The ClinicalTrials.gov registry entry for NCT07348237 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which MK-2828 is the first listed.
NCT07348237 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07348237 about?
NCT07348237 is a clinical study titled "A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)". The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
What is the current status of trial NCT07348237?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-03-02. Estimated completion is 2026-08-18.
What conditions does trial NCT07348237 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Renal Impairment, Chronic Kidney Failure.
What interventions are being tested in trial NCT07348237?
The interventions under investigation include: MK-2828 (DRUG).
Who is sponsoring clinical trial NCT07348237?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07348237 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.